These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 30204795)

  • 1. Relationship between low levels of circulating TRAIL and atheromatosis progression in patients with chronic kidney disease.
    Arcidiacono MV; Rimondi E; Maietti E; Melloni E; Tisato V; Gallo S; Valdivielso JM; Fernández E; Betriu À; Voltan R; Zauli G; Volpato S; Secchiero P
    PLoS One; 2018; 13(9):e0203716. PubMed ID: 30204795
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Soluble TWEAK and atheromatosis progression in patients with chronic kidney disease.
    Fernández-Laso V; Méndez-Barbero N; Valdivielso JM; Betriu A; Fernández E; Egido J; Martín-Ventura JL; Blanco-Colio LM
    Atherosclerosis; 2017 May; 260():130-137. PubMed ID: 28390291
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Predictors of Subclinical Atheromatosis Progression over 2 Years in Patients with Different Stages of CKD.
    Gracia M; Betriu À; Martínez-Alonso M; Arroyo D; Abajo M; Fernández E; Valdivielso JM;
    Clin J Am Soc Nephrol; 2016 Feb; 11(2):287-96. PubMed ID: 26668022
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Circulating angiotensin converting enzyme 2 activity as a biomarker of silent atherosclerosis in patients with chronic kidney disease.
    Anguiano L; Riera M; Pascual J; Valdivielso JM; Barrios C; Betriu A; Clotet S; Mojal S; Fernández E; Soler MJ;
    Atherosclerosis; 2016 Oct; 253():135-143. PubMed ID: 27615597
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Factors predicting cardiovascular events in chronic kidney disease patients. Role of subclinical atheromatosis extent assessed by vascular ultrasound.
    Valdivielso JM; Betriu A; Martinez-Alonso M; Arroyo D; Bermudez-Lopez M; Fernandez E;
    PLoS One; 2017; 12(10):e0186665. PubMed ID: 29045466
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Soluble TWEAK and Major Adverse Cardiovascular Events in Patients with CKD.
    Fernández-Laso V; Sastre C; Valdivielso JM; Betriu A; Fernández E; Egido J; Martín-Ventura JL; Blanco-Colio LM
    Clin J Am Soc Nephrol; 2016 Mar; 11(3):413-22. PubMed ID: 26728587
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Association of serum phosphorus with subclinical atherosclerosis in chronic kidney disease. Sex makes a difference.
    Martín M; Valls J; Betriu A; Fernández E; Valdivielso JM
    Atherosclerosis; 2015 Jul; 241(1):264-70. PubMed ID: 25748053
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prevalence of subclinical atheromatosis and associated risk factors in chronic kidney disease: the NEFRONA study.
    Betriu A; Martinez-Alonso M; Arcidiacono MV; Cannata-Andia J; Pascual J; Valdivielso JM; Fernández E;
    Nephrol Dial Transplant; 2014 Jul; 29(7):1415-22. PubMed ID: 24586070
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Observational multicenter study to evaluate the prevalence and prognosis of subclinical atheromatosis in a Spanish chronic kidney disease cohort: baseline data from the NEFRONA study.
    Arroyo D; Betriu A; Martinez-Alonso M; Vidal T; Valdivielso JM; Fernández E;
    BMC Nephrol; 2014 Oct; 15():168. PubMed ID: 25326683
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Association of the rs495392 Klotho polymorphism with atheromatosis progression in patients with chronic kidney disease.
    Valdivielso JM; Bozic M; Galimudi RK; Bermudez-López M; Navarro-González JF; Fernández E; Betriu À
    Nephrol Dial Transplant; 2019 Dec; 34(12):2079-2088. PubMed ID: 30010839
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Association of FGF-2 Concentrations with Atheroma Progression in Chronic Kidney Disease Patients.
    Bozic M; Betriu A; Bermudez-Lopez M; Ortiz A; Fernandez E; Valdivielso JM;
    Clin J Am Soc Nephrol; 2018 Apr; 13(4):577-584. PubMed ID: 29519952
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Osteoprotegerin and osteoprotegerin/TRAIL ratio are associated with cardiovascular dysfunction and mortality among patients with renal failure.
    Kuźniewski M; Fedak D; Dumnicka P; Stępień E; Kuśnierz-Cabala B; Cwynar M; Sułowicz W
    Adv Med Sci; 2016 Sep; 61(2):269-275. PubMed ID: 27128817
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Association of serum TRAIL levels with atherosclerosis in patients with type 2 diabetes mellitus.
    Kawano N; Mori K; Emoto M; Lee E; Kobayashi I; Yamazaki Y; Urata H; Morioka T; Koyama H; Shoji T; Nishizawa Y; Inaba M
    Diabetes Res Clin Pract; 2011 Mar; 91(3):316-20. PubMed ID: 21227528
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Diabetic nephropathy is an independent factor associated to severe subclinical atheromatous disease.
    Barrios C; Pascual J; Otero S; Soler MJ; Rodríguez E; Collado S; Faura A; Mojal S; Navarro-González JF; Betriu A; Fernandez E; Valdivielso JM;
    Atherosclerosis; 2015 Sep; 242(1):37-44. PubMed ID: 26177272
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prevalence and progression of subclinical atherosclerosis in patients with chronic kidney disease and diabetes.
    Palanca A; Castelblanco E; Perpiñán H; Betriu À; Soldevila B; Valdivielso JM; Bermúdez M; Duran X; Fernández E; Puig-Domingo M; Groop PH; Alonso N; Mauricio D
    Atherosclerosis; 2018 Sep; 276():50-57. PubMed ID: 30032025
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The circulating soluble TRAIL is a negative marker for inflammation inversely associated with the mortality risk in chronic kidney disease patients.
    Liabeuf S; Barreto DV; Barreto FC; Chasseraud M; Brazier M; Choukroun G; Kamel S; Massy ZA
    Nephrol Dial Transplant; 2010 Aug; 25(8):2596-602. PubMed ID: 20190248
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Soluble TWEAK is associated with atherosclerotic burden in patients with chronic kidney disease.
    Valdivielso JM; Coll B; Martín-Ventura JL; Moreno JA; Egido J; Fernández E; Blanco-Colio LM
    J Nephrol; 2013; 26(6):1105-13. PubMed ID: 23475462
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Association of ALOX12 gene polymorphism with all-cause and cardiovascular mortality in diabetic nephropathy.
    Roumeliotis AK; Roumeliotis SK; Panagoutsos SA; Tsetsos F; Georgitsi M; Manolopoulos V; Paschou P; Passadakis PS
    Int Urol Nephrol; 2018 Feb; 50(2):321-329. PubMed ID: 29196930
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Elevated Circulating Osteoprotegerin Levels in the Plasma of Hemodialyzed Patients With Severe Artery Calcification.
    Krzanowski M; Krzanowska K; Dumnicka P; Gajda M; Woziwodzka K; Fedak D; Grodzicki T; Litwin JA; Sułowicz W
    Ther Apher Dial; 2018 Oct; 22(5):519-529. PubMed ID: 29974642
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Advanced chronic kidney disease populations have elevated trimethylamine N-oxide levels associated with increased cardiovascular events.
    Kim RB; Morse BL; Djurdjev O; Tang M; Muirhead N; Barrett B; Holmes DT; Madore F; Clase CM; Rigatto C; Levin A;
    Kidney Int; 2016 May; 89(5):1144-1152. PubMed ID: 27083288
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.